Inari Medical
Medical device company developing devices for the interventional treatment of cardiovascular diseases.
Launch date
Employees
Market cap
CAD3.7b
Enterprise valuation
CAD3.6b (Public information from Sep 2024)
Share price
$43.84 NARI
Aliso Viejo California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 140m | 277m | 383m | 494m | 600m | 709m | 829m |
| % growth | 173 % | 98 % | 38 % | 29 % | 22 % | 18 % | 17 % |
| EBITDA | 18.2m | 11.0m | (25.9m) | 15.2m | (33.4m) | 13.1m | 44.2m |
| % EBITDA margin | 13 % | 4 % | (7 %) | 3 % | (6 %) | 2 % | 5 % |
| Profit | 13.8m | 9.8m | (29.3m) | (1.6m) | (62.7m) | 2.0m | 26.4m |
| % profit margin | 10 % | 4 % | (8 %) | - | (10 %) | - | 3 % |
| EV / revenue | 29.3x | 15.9x | 8.0x | 7.3x | 4.0x | 3.3x | 2.8x |
| EV / EBITDA | 224.1x | 401.3x | -119.1x | 238.7x | -72.5x | 180.4x | 53.0x |
| R&D budget | 18.4m | 51.0m | 74.2m | 87.5m | - | - | - |
| R&D % of revenue | 13 % | 18 % | 19 % | 18 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$4.7m | Series A | ||
$12.4m | Series B | ||
| N/A | $6.1m | Series C | |
$20.9m | Series C | ||
| N/A | N/A | IPO | |
| Total Funding | CAD60.1m | ||
